Drug Discovery Weekly — 2026-09-14
Scholar Rock secured a landmark FDA approval for Isembyld, the first drug targeting muscle loss in spinal muscular atrophy, marking a significant clinical win for SMA patients. Meanwhile, access issues for the recently approved pancreatic cancer drug Rasonque highlight ongoing insurance hurdles despite regulatory success. <!-- /headline --> FDA Approves First Drug Targeting SMA Muscle Loss; Access Barriers Persist for Pancreatic Cancer Drug
Drug Discovery Weekly — 2026-09-14
FDA & Regulatory Decisions
Isembyld (Scholar Rock) — Approval
- Indication: Spinal Muscular Atrophy (SMA)
- Significance: This is the first FDA-approved drug specifically targeting muscle loss associated with SMA. It is approved for adults and children 2 years and older who are currently receiving SMA therapies that target SMN2. The approval is based on a late-stage clinical trial showing statistically significant improvements in motor skills compared to placebo.
- Timeline: Available now for eligible patients on existing SMA therapies.
Rasonque (Revolution Medicines) — Approval Follow-up
- Indication: Pancreatic Cancer
- Significance: While not a new approval this week, the September 8th reporting highlights the critical post-approval phase for Rasonque (daraxonrasib), which was approved in late August. The drug is expected to usher in a new era of treatment, but patients are facing significant delays in insurance coverage, taking weeks to catch up with the FDA decision.
- Timeline: Ongoing rollout and insurance authorization processes.
Clinical Trial Milestones
No recent Phase 2/3 readouts or trial initiations published after 2026-09-07 were found in the provided research results. The available data references trials from earlier in 2026 or upcoming events later in the year.
Pharma Deals & M&A
Investor Sentiment & Strategy: Novartis
- Deal Context: Recent reports indicate that Novartis shareholders have expressed deepened trust issues regarding the company's M&A strategy. This comes amid a broader context where biopharma dealmaking in 2026 has already exceeded previous years' totals, driven by patent expiries and pipeline urgency.
Note: No specific new acquisition or licensing agreements with definitive terms were published in the last 7 days in the provided sources.
AI & Computational Drug Discovery
No new AI/ML-specific drug discovery advances or announcements were published in the provided research results between 2026-09-07 and 2026-09-14. Existing literature reviews from July and August 2026 discuss the general state of AI in drug discovery but do not constitute new developments within this week's coverage period.
Pipeline Watch: Key Upcoming Catalysts
- September 2026: PDUFA dates for Zidesamtinib and Ameluz®PDT are noted as significant events for this month. Investors are advised to monitor these dates for potential regulatory decisions.
Week in Context
This week's primary development centers on the FDA's approval of Scholar Rock's Isembyld, representing a crucial expansion of the therapeutic arsenal for Spinal Muscular Atrophy. By targeting muscle loss directly rather than just addressing the underlying genetic deficiency via SMN2, Isembyld offers a complementary mechanism that has shown to improve motor skills in a statistically significant manner. This approval underscores the industry's continued progress in refining treatments for rare diseases, moving beyond single-mechanism therapies to combination approaches that address multiple facets of disease pathology.
Simultaneously, the reporting on Rasonque highlights a persistent structural challenge in modern drug delivery: the gap between regulatory approval and patient access. Despite the "practice-changing" nature of the pancreatic cancer drug approved by the FDA in August, insurance lag times are creating real-world barriers for patients. This dichotomy—rapid regulatory advancement versus slow administrative adoption—remains a critical friction point in the pharmaceutical value chain, suggesting that future strategic planning must account for payer engagement as early as clinical trial design.
In the M&A landscape, while no massive new deals broke this week, the scrutiny on Novartis' strategy reflects broader investor anxiety about how large pharma companies are deploying capital to offset patent cliffs. With 2026 deal values already surpassing previous records, the market is watching closely to see if companies like Novartis can align their acquisition strategies with shareholder expectations for long-term value creation rather than just short-term pipeline replenishment.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
